Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of E-52862 in the early treatment of confirmed mild symptomatic COVID-19 patients
2020-003603-33Phase 2Completed
- Sponsor
- Parc de Salut Mar
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of E-52862 in coronavirus disease 2019 (COVID-19), sponsored by Parc de Salut Mar. Primary endpoint: Change in SARS-CoV-2 viral load from baseline to day 7. Started Oct 2020; status: completed.
02
Drugs
E-52862
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-003603-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003603-33.